Physician profile
Amanda Mims
NPI 1174173322
$1,723.45
in general payments reported to CMS, 2019-2025
20 companies · $668 in 2025
The $668 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $108 · 2022: $222 · 2023: $322 · 2024: $404 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,195 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,195.14 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $455.68 | 2024-2025 | Erleada, Rybrevant, Carvykti |
| Axonics, INC. | $420.71 | 2022-2023 | Axonics |
| Endo USA, INC. | $201.02 | 2024-2025 | Xiaflex |
| Sumitomo Pharma America, INC. | $122.18 | 2023-2025 | Gemtesa |
| Ferring Pharmaceuticals INC. | $73.15 | 2021-2025 | Adstiladrin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.54 | 2021 | |
| Astellas Pharma US INC | $68.20 | 2022-2024 | Myrbetriq, Veozah, Xtandi |
| Dexcom, INC. | $66.96 | 2025 | Dexcom G6 Transmitter |
| Halozyme INC | $38.33 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.24 | 2025 | |
| Phadia US INC. | $22.60 | 2024 | Immunocap |
| Pfizer INC. | $21.38 | 2024 | |
| Lilly USA, LLC | $21.38 | 2025 | Kisunla, Amyvid |
| Fidia Pharma USA INC. | $20.07 | 2021 | |
| Biogen, INC. | $18.35 | 2024 | Skyclarys |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $18.28 | 2025 | Axonics |
| Tolmar Pharmaceuticals, INC. | $15.25 | 2022 | |
| Antares Pharma, INC. | $15.19 | 2024 | Xyosted |
| Olympus America INC. | $14.63 | 2024 | Itind System |
| Abbvie INC. | $14.31 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Mims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.